SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Mixed quarterly results and an unchanged full-year outlook are fueling debate, with softer bookings and conservative guidance weighing against reported exceptional GTA VI preorders and the games scheduled launch. Bulls see the release as a major growth catalyst, while skeptics warn expectations may already be priced in and the stock could see a sell-the-news reaction.

Avalanche (AVAX) is a cryptocurrency launched in 2020. Avalanche has a current supply of 470,841,831.5537221 with 445,839,831.5537221 in circulation. The last known price of Avalanche is 8.67923054 USD and is up 8.47 over the last 24 hours. It is currently trading on 1134 active market(s) with $528,273,140.94 traded over the last 24 hours. More information can be found at https://avax.network/.

Avalanche

Avalanche is drawing attention after traders discussed the NYSE selecting its blockchain for an upcoming tokenized-securities trading and settlement platform. Reactions are mixed: some view the institutional tokenization news as bullish, while others say AVAXs price response has been modest and fading, and remains sensitive to Bitcoins direction.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Q3 results disappointed investors, with an unexpected loss, margin pressure, fewer subscribers sequentially and a reduced profit outlook driving the sharp selloff. Traders are split between concerns about near-term profitability and subscriber momentum and optimism that the Lilly partnership and planned peptides launch could support future growth.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A quarterly earnings beat, stronger-than-expected Q4 guidance, and expanded buyback authorization drove a sharp rally, but shares gave back much of the after-hours surge during managements call. Traders debated whether the results signal a turnaround or a short squeeze, with skeptics citing weak underlying growth, margin pressure, and doubts about management.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs quarterly results are driving attention: revenue and backlog growth and an above-consensus outlook are offset by a wider-than-expected loss, prompting a post-earnings pullback. Bulls point to Iridium-related one-time costs and strong Neutron bookings, while skeptics focus on Neutrons delayed first launch and ongoing execution and profitability risks.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent is rebounding amid a volatile reaction to strong quarterly results and upbeat guidance, with traders pointing to AI data-center demand for optical components. Bulls see the selloff as overdone and the growth outlook as intact, while bears remain concerned about broader AI-capex uncertainty and further profit-taking.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Deramiocels HOPE-3 cardiac results received an American Heart Association research award, drawing renewed attention ahead of the FDAs November 22 decision. Traders are largely bullish on approval, while debate remains over the awards significance and whether the review will focus on the amended upper-limb indication or the disputed cardiac data.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Discussion centers on Corvus soquelitinib pipeline and the prospect of future clinical data, with bullish traders emphasizing its potential across cancer and inflammatory diseases while skeptics cite delayed readouts, limited evidence, and execution concerns. Posts also highlight reported institutional and insider buying, while buyout and short-squeeze claims remain speculation.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs quarterly report is driving discussion, with traders weighing an earnings beat against weaker revenue linked to lower Bitcoin prices. Reactions are split: some welcome debt reduction and the buyback authorization, while others discount the results because of unrealized Bitcoin gains and criticize the lack of signed AI/HPC tenant deals.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is being tied to Google Cloud using its EPYC processors in TPU infrastructure and an Oppenheimer upgrade, with traders also speculating that Nvidia-related uncertainty is prompting a rotation toward chip rivals. Bulls see stronger AI-infrastructure positioning and momentum, while skeptics warn the sharp run-up may fade and question AMDs valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Sweetgreen, Inc. (SG) a Strong Momentum Stock: Buy Now?

Does Sweetgreen, Inc. (SG) have what it takes to be a top stock pick for momentum investors? Let's find out.

Sweetgreen: 3 Key Takeaways for Long-Term Investors

Key PointsOctober comparable sales rose 5% with 4% transaction growth...

Sweetgreen Is Finally Growing Again. Time To Buy?

Key PointsSweetgreen says its turnaround plan is delivering results...

Here's What Key Metrics Tell Us About Sweetgreen (SG) Q3 Earnings

Although the revenue and EPS for Sweetgreen (SG) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sweetgreen, Inc. (SG) Reports Q3 Loss, Beats Revenue Estimates

Sweetgreen (SG) delivered earnings and revenue surprises of +17.86% and +4.41%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Sweetgreen, Inc. Announces Third Quarter 2026 Financial Results

Sweetgreen, Inc. (NYSE: SG) (the Company), the mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale, today announced financial results for its third fiscal quarter ended September 27, 2026. Third quarter 2026 financial highlights For the third quarter of...

SG, SHAK & PZZA: Can These Restaurant Stocks Beat Q3 Estimates?

Sweetgreen, Shake Shack and Papa John's gear up for Q3 results as value deals, digital initiatives and rising costs shape restaurant sector performance.

McDonald's (MCD) Beats Q3 Earnings Estimates

McDonald's (MCD) delivered earnings and revenue surprises of +6.25% and -1.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Sony's Q2 Earnings on Deck: Can Gaming Maintain Its Profit Growth?

SONY's Q2 earnings outlook hinges on PlayStation engagement, music growth and image sensor demand. Earthquake disruptions and forex fluctuations pose risks.

Wayfair Before Q3 Earnings: What's in the Cards for the Stock?

W heads into Q3 earnings with 7.84% revenue growth estimated, supported by stronger orders and loyalty gains, even as housing and overseas demand weigh.

• Reported GAAP EPS of -$0.26 up 16.13% YoY
• Reported revenue of $176.02M up 2.11% YoY
• Sweetgreen updated FY2026 guidance to Same-Store Sales Change of about (5.5)%, Restaurant-Level Profit Margin of 11.0% to 11.5%, and Adjusted EBITDA between -$23M to -$20M.

Sweetgreen reported (6.4)% Same-Store Sales Change amid outbreak-related traffic declines, lower Restaurant-Level Profit Margin with higher labor expenses, and Adjusted EBITDA losses; FY2027 openings are expected about half FY2026.

Sweetgreen grew Q3 revenue alongside new restaurant contributions, increased digital revenue mix, and reported improved operating-loss margin; management also cited positive comparable sales in October, primarily driven by transaction growth.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Stocktwits Wall Street Wrap: Analysts Turn Bullish On Sweetgreen, Target And Airbnb – Liquidia And FICO Face Downgrades

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Wells Fargo upgraded Sweetgreen and raised its price target, citing easing Cyclospora concerns and improving traffic.&nbsp;</li><li>HSBC upgraded Target, while KeyBanc raised Airbnb on durable growth and hotel expansion potential.&nbsp;</li><li>Wells Fargo and BTIG downgraded Liquidia after a court found Yutrepia infringed United Therapeutics patents.&nbsp;</li></ul><p>Six stocks are drawing fresh attention after Wall Street analysts changed their views on everything from restaurant traffic and retail demand to travel growth, patent risks and credit-score competition. Sweetgreen Inc. (SG), Target Corp. (<a class="mention" data-mention="$TGT" data-symbol-id="TGT" href="https://stocktwits.com/symbol/TGT" target="_blank">TGT</a>) and Airbnb Inc. (ABNB) received upgrades, while Liquidia Corp. (LQDA), Sea Ltd. (SE) and Fair Isaac Corp. (FICO) faced downgrades or sharply lower price targets.&nbsp;</p><h2 class="st-heading-2">Cyclospora Concerns Ease As Sweetgreen Traffic Shows Signs Of Recovery&nbsp;</h2><p>Wells Fargo upgraded Sweetgreen to ‘Overweight’ from ‘Equal Weight’ and lifted its price target to $11 from $6 after discussions with management. The firm said concerns tied to the Cyclospora outbreak appear to be easing, while Sweetgreen’s operational changes are starting to show results.</p><p>Wells Fargo said Sweetgreen was not responsible for the Cyclospora incident, but the episode hurt demand across the salad category. The company now sees customer traffic improving, while the analyst expects management could rely more on pricing to help absorb higher costs.</p><p>Sweetgreen shares have fallen 80% from their November 2024 peak, but improving traffic, new wraps and the end of the Cyclospora outbreak could support a recovery.&nbsp;<a href="https://stocktwits.com/symbol/SG">Sweetgreen stock</a> has gained over 5% so far this week and is on track for a fourth week of gains.&nbsp;</p><figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20261002_054252505_d7d79db7eb.png" alt="koyfin_20261002_054252505.png" width="2400" height="1240"></figure><h2 class="st-heading-2">HSBC Turns Bullish On Target, Airbnb Could Grow Beyond Core Rentals&nbsp;</h2><p>HSBC upgraded Target to ‘Buy’ from ‘Hold’ and raised its price target to $190 from $125. Analyst Joe Thomas pointed to the retailer’s Q2 performance as evidence that customer visits are improving and that its turnaround efforts are gaining traction. HSBC also sees room for earnings to surpass current expectations.</p><p>KeyBanc&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/abnb-stock-eyes-snapping-4-week-losing-streak-key-banc-upgrades-airbnb-on-hotel-growth-valuation/cZDSvbKRB0m">upgraded</a> Airbnb to ‘Overweight’ from ‘Sector Weight’ and set a $191 price target. Analyst Sergio Segura said Airbnb’s main business continues to grow steadily, while hotel bookings could become a new source of growth.&nbsp;</p><p>While&nbsp;<a href="https://stocktwits.com/symbol/TGT">Target stock</a> was down 0.4% this week,&nbsp;<a href="https://stocktwits.com/symbol/ABNB">Airbnb stock</a> has gained nearly 2%.&nbsp;</p><h2 class="st-heading-2">Yutrepia Patent Dispute Creates Fresh Uncertainty For Liquidia&nbsp;</h2><p>Wells Fargo downgraded Liquidia to ‘Equal Weight’ from ‘Overweight’ and slashed its target to $30 from $108. The firm cited greater uncertainty for the company after a court&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lqda-stock-eyes-worst-day-ever-after-judge-upholds-two-uthr-patent-claims/cZMFSOCRBL0">ruling</a> and expressed limited confidence that Liquidia will prevail on appeal.</p><p>A Delaware judge ruled that Liquidia’s Yutrepia infringes two United Therapeutics (UTHR) patent claims. Both offer inhaled treprostinil treatments for pulmonary arterial hypertension (PAH) and PH-ILD . United sells Tyvaso products, while Liquidia’s Yutrepia, approved in 2025, is a dry-powder competitor. The disputed patent covers using inhaled treprostinil to improve exercise ability in PH-ILD patients.&nbsp;</p><p>BTIG separately lowered Liquidia to ‘Neutral’ from ‘Buy’, citing that the judgment could potentially halt Yutrepia across indications until the pulmonary hypertension indication is removed from its label.&nbsp;<a href="https://stocktwits.com/symbol/LQDA">Liquidia stock&nbsp;</a>is on track for its worst week ever with a 59% crash.</p><h2 class="st-heading-2">DBS Bank Cuts Sea Rating While BofA Flags Risks For FICO&nbsp;</h2><p>DBS Bank downgraded Sea to ‘Hold’ from ‘Buy’ and cut its price target to $105 from $148. The firm said Shopee is gaining strength but higher spending is hurting margins. It also faces competition from PDD’s cross-border business and Shopee’s push into quick commerce.&nbsp;</p><p>BofA moved Fair Isaac to ‘Neutral’ from ‘Buy’ and cut its price target to $700 from $1,400 after the Federal Housing Finance Agency placed VantageScore 4.0 and Classic FICO on the same loan-pricing adjustment framework. BofA said the change could encourage lenders to consider VantageScore more widely, creating additional risks for FICO’s pricing, volume and market share.</p><p><a href="https://stocktwits.com/symbol/SE">Sea stock</a> is heading for a fifth straight week of losses, with a 4.3% decline, while&nbsp;<a href="https://stocktwits.com/symbol/FICO">Fair Isaac stock</a> is down 23% and is on track for its worst month since March.&nbsp;</p><p>So far this year, SG, <a class="mention" data-mention="$TGT" data-symbol-id="TGT" href="https://stocktwits.com/symbol/TGT" target="_blank">TGT</a> and ABNB stocks gained between 18% and 60%, while LQDA, SE and FICO stocks crashed between 18% and 60%&nbsp;</p><p>Also see:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nke-stock-heads-for-a-weekly-loss-morningstar-says-nike-s-fresh-cost-cuts-signal-a-longer-road-to-recovery/cZDj37eRBKb">NKE Stock Heads For A Weekly Loss: Morningstar Says Nike's Fresh Cost Cuts Signal A Longer Road To Recovery</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Shoppers walk past the entrance to a Target store in Washington, DC.

Six stocks are drawing fresh attention after Wall Street analysts changed their views on everything from restaurant traffic and retail demand to travel growth, patent risks and credit-score competition. Sweetgreen Inc. (SG), Target Corp. (TGT) and Airbnb 

The changes reflect new views on restaurant demand, retail traffic, travel growth, drug risks and competition in financial data.


Airbnb Inc

Fair, Isaac Corp.

Liquidia Corp

Sea Ltd - ADR

Target Corp

Yes, buying

No, staying away

Just holding what I have

Watching for a better entry

Sweetgreen shares tanked over 24% in a month during the cyclospora outbreak, but are up over 18% today after investigators tied the illness to Taco Bell's lettuce supplier - not Sweetgreen. Are you buying $SG on the dip? Explain your reasoning in the comments.

Sweetgreen ($SG) was not linked to the cyclospora outbreak - are you a buyer of the stock?

Stocktwits

) was not linked to the cyclospora outbreak - are you a buyer of the stock?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.23	--	--	N/A
Q3 '26	-$0.26	-$0.24	8.78%	BEAT
Q2 '26	-$0.13	-$0.19	-50.19%	MISSED
Q1 '26	-$0.22	-$0.27	-21.89%	MISSED
Q4 '25	-$0.31	-$0.40	-28.70%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

SG Earnings

Latest Earnings Results: Q3 '26

Historical Earnings